NMDP BioTherapies Relaunches Premium Services Supporting Autologous Cell Therapies

Return to autologous business driven by loyal cell and gene biotechnology customers seeking a comprehensive solution for improved supply chain and resource efficiencies with a white glove support model Industry-leading apheresis network support and managed logistics to enable consistent harvest and reliable delivery of autologous starting material and manufactured product MINNEAPOLIS–(BUSINESS WIRE)–NMDP BioTherapiesSM (formerly known…

NMDP BioTherapies and the NMDP BioTherapies Cord Blood Bank Alliance Introduce Optimal Cord Blood Units for Manufacture of NK Cell Therapies And Other Cord Derived Cell Therapies

Leveraging the Power of the NMDP BioTherapies Cord Blood Bank Alliance, Readily Accessible Cord Blood Units That Meet the Criteria Established in Marin, et al in Nature Medicine for Production of CAR-NK Cells MINNEAPOLIS–(BUSINESS WIRE)–NMDP BioTherapiesSM (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, and the NMDP…

BlueSphere Bio To Partner with NMDP BioTherapies℠ for the Company’s First-In-Human TCR-based Product Candidate in Combination with Allogeneic Hematopoietic Cell Transplantation Trial

Through this partnership, BlueSphere will treat patients with acute myeloid and lymphocytic leukemia, and myeloid dysplastic syndrome, who have active disease or are at high risk for relapse, with the goal of reducing the rate of relapse and graft versus host disease NMDP BioTherapies will provide bioinformatics consulting to help identify donors and will manage supply chain logistics to…

NMDP BioTherapies to Present Data at ISCT 2024 on the Stability of Infectious Disease Marker Analytes During Donor Qualification for Allogeneic Cell Therapies

Study in conjunction with investigators from Labor Quade and the Johns Hopkins School of Medicine analyzed the longer-term stability of IDM analytes in uncentrifuged peripheral blood samples to allow for increased flexibility in donor sample processing. Study results indicate that broad use of blood processing parameters developed for the measure of metabolites appears to create…

NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development

First of Its Kind Clinical-Grade Leukopak Now Facilitates Easier Regulatory Filing with Access to a DMF and Identification of Additional Characteristics Required to Qualify Cord Blood Units as Starting Material for Manufacture of Cell and Gene Therapies MINNEAPOLIS, April 16, 2024 — NMDP BioTherapiesSM (formerly known as the Be The Match BioTherapies), a leader in cell…

International regulations for allogeneic cell source material

Allogeneic Cell Sourcing, Industry Updates

When you procure cellular starting material or distribute a cell or gene therapy product across international borders, you must consider the country or regional regulatory requirements at play and where they diverge. Allogeneic cell therapy sponsors face common challenges when treating a global patient population with therapies using healthy adult donor starting material.